A detailed history of Mercer Global Advisors Inc transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Mercer Global Advisors Inc holds 16,959 shares of IBRX stock, worth $35,274. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,959
Previous 36,824 53.95%
Holding current value
$35,274
Previous $97,000 57.73%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

SELL
$2.24 - $3.01 $44,497 - $59,793
-19,865 Reduced 53.95%
16,959 $41,000
Q2 2025

Aug 14, 2025

BUY
$1.89 - $3.44 $69,597 - $126,674
36,824 New
36,824 $97,000
Q4 2024

Feb 14, 2025

BUY
$2.56 - $6.17 $21,399 - $51,575
8,359 Added 29.18%
37,006 $94,000
Q3 2024

Nov 13, 2024

BUY
$3.32 - $6.7 $29,026 - $58,578
8,743 Added 43.93%
28,647 $106,000
Q2 2024

Aug 12, 2024

BUY
$4.82 - $9.15 $95,937 - $182,121
19,904 New
19,904 $125,000

Others Institutions Holding IBRX

About ImmunityBio, Inc.


  • Ticker IBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 400,304,000
  • Market Cap $833M
  • Description
  • ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...
More about IBRX
Track This Portfolio

Track Mercer Global Advisors Inc Portfolio

Follow Mercer Global Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mercer Global Advisors Inc , based on Form 13F filings with the SEC.

News

Stay updated on Mercer Global Advisors Inc with notifications on news.